Literature DB >> 36262675

Post-resection emphysematous prostatitis due to multi-resistant Enterobacter cloacae complex: A case of successful conservative management.

Nedjim Abdelkerim Saleh1, Mahamat Ali Mahamat2, Moataz Amine1, Dakir Mohamed1, Debbagh Adil1.   

Abstract

Emphysematous prostatitis is a rare complication of bacterial prostatitis with a high mortality rate. Due to limited publications on this entity, its management is not standardized. In the reported cases, the treatment consisted of rapid and complete drainage of the abscess, with early antibiotic therapy. We report a case of emphysematous prostatitis in a 76-year-old patient at D17 of a prostatic resection who presented to the emergency room with asthenia and fever. Clinically, he was in sepsis. The isolated germ is an Enterococcus Enterobacter cloacae complex, sensitive to Piperacillin + Tazobactam. The ultimate evolution was favorable.
© 2022 Published by Elsevier Inc.

Entities:  

Year:  2022        PMID: 36262675      PMCID: PMC9574411          DOI: 10.1016/j.eucr.2022.102249

Source DB:  PubMed          Journal:  Urol Case Rep        ISSN: 2214-4420


  4 in total

Review 1.  Emphysematous prostatic abscess: case series study and review.

Authors:  Sheng-Chen Wen; Yung-Shun Juan; Chii-Jye Wang; Ko Chang; Ming-Chen Paul Shih; Jung-Tsung Shen; Wen-Jeng Wu; Mei-Yu Jang
Journal:  Int J Infect Dis       Date:  2012-03-17       Impact factor: 3.623

2.  Emphysematous prostatic abscess: diagnosis and treatment.

Authors:  A J Mariani; L D Jacobs; P R Clapp; A Hariharan; U K Stams; C V Hodges
Journal:  J Urol       Date:  1983-02       Impact factor: 7.450

3.  Multidrug-Resistant Enterobacter cloacae Complex Emerging as a Global, Diversifying Threat.

Authors:  Medini K Annavajhala; Angela Gomez-Simmonds; Anne-Catrin Uhlemann
Journal:  Front Microbiol       Date:  2019-01-31       Impact factor: 5.640

Review 4.  Emphysematous prostatic abscess due to candidiasis: A case report and review of the literature.

Authors:  Zhongyi Li; Jiaming Wen; Nan Zhang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.